BRIEF Teva loses Seroquel decision A US federal court upheld AstraZeneca s patent Teva will appeal: related news

BRIEF: Teva loses Seroquel decision: A US federal court upheld AstraZeneca's patent. Teva will appeal.

TMCNet: BRIEF: Teva loses Seroquel decision: A US federal court upheld AstraZeneca's patent. Teva will appeal.

Teva: Court rules for AstraZeneca in Seroquel patent case; Teva to appeal

SAN FRANCISCO (Thomson Financial) - Teva Pharmaceutical Industries Ltd. late Tuesday said a district court has ruled in favor of AstraZeneca plc in a patent dispute over a generic version of AstraZeneca's bipolar disorder treatment Seroquel.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R) (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca AZN today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R) (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca AZN today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R) (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R) (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN - News) today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL® (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Teva loses patent dispute, plans appeal

Teva Pharmaceutical Industries Ltd. said Tuesday a U.S. court ruled against it in an ongoing patent challenge over the anti-psychotic drug Seroquel and the Israel-based drug developer plans to appeal the decision.

U.S. Federal Circuit Court of Appeals Fully Upholds Eisai's Favorable Ruling in Aciphex Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories

TOKYO and WOODCLIFF LAKE, N.J., July 21, 2008 /PRNewswire/ -- With respect to Eisai's patent infringement lawsuit against Teva Pharmaceuticals and Dr. Reddy's Laboratories concerning Aciphex(R) (generic name: rabeprazole sodium tablets, Product Name in Japan: Pariet(R)), Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announce that the United States Court of Appeals for the Federal Circuit has affirmed both the United States District Court for the Southern District of New York's summary judgment ruling on the validity of Eisai's composition of matter patent and its ruling on the enforceability of the composition of matter patent.

Teva loses patent dispute, plans appeal

NEW YORK (AP) - Teva Pharmaceutical Industries Ltd. said Tuesday a U.S. court ruled against it in an ongoing patent challenge over the anti-psychotic drug Seroquel and the Israel-based drug developer plans to appeal the decision.

Teva loses patent dispute, plans appeal

NEW YORK (AP) -- Teva Pharmaceutical Industries Ltd. said Tuesday a U.S. court ruled against it in an ongoing patent challenge over the anti-psychotic drug Seroquel and the Israel-based drug developer plans to appeal the decision.

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,� said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

Teva Pharmaceutical Industries loses patent challenge to blockbuster drug, plans appeal

NEW YORK (AP) - Teva Pharmaceutical Industries Ltd. said Tuesday a U.S. court ruled against it in an ongoing patent challenge over the anti-psychotic drug Seroquel and the Israel-based drug developer plans to appeal the decision.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Teva: Court rules for AstraZeneca in Seroquel patent case; Teva to appeal

The summer box office often sizzles as the calendar turns to July. What movies have opened best on the Independence Day holiday weekend?

AstraZeneca Gets Favorable Ruling In Seroquel Patent Litigation - Update

(RTTNews) - AstraZeneca plc (AZN: News, Chart, Quote ), a manufacturer of pharmaceuticals, Tuesday received a motion for summary judgment of no inequitable conduct by the US District Court in a lawsuit against Teva Pharmaceutical Industries Ltd. (TEVA) and Sandoz, Inc. for alleged infringement of AstraZeneca's patent.

Applied Nanotech Holdings, Inc. Announces Court Decision

Applied Nanotech Holdings, Inc. (OTCBB: APNT) announced that the U.S. Court of Appeals for the Fifth Circuit issued its opinion in its litigation with Canon, Inc. The appeals court in part affirmed, and in part reversed, the rulings of the district court. While the appeals court accepted, without deciding, the district court's decision that SED, Inc. as originally formed did not qualify as a Canon subsidiary, and that Canon had materially breached the contract, it found that termination of the license agreement was not an appropriate remedy. The appeals court also ruled that the restructured SED, Inc., which is 100% owned by Canon, now qualifies as a Canon subsidiary. The appeals court denied Applied Nanotech's appeal that the district court had improperly excluded certain evidence from the trial.

Applied Nanotech Holdings, Inc. Announces Court Decision

Applied Nanotech Holdings, Inc. (OTCBB: APNT) announced that the U.S. Court of Appeals for the Fifth Circuit issued its opinion in its litigation with Canon, Inc. The appeals court in part affirmed, and in part reversed, the rulings of the district court. While the appeals court accepted, without deciding, the district court's decision that SED, Inc. as originally formed did not qualify as a Canon subsidiary, and that Canon had materially breached the contract, it found that termination of the license agreement was not an appropriate remedy. The appeals court also ruled that the restructured SED, Inc., which is 100% owned by Canon, now qualifies as a Canon subsidiary. The appeals court denied Applied Nanotech's appeal that the district court had improperly excluded certain evidence from the trial.

Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants

Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Energizer Holdings, Inc. Files Patent Infringement Complaint in Federal Court Against...

Energizer Holdings, Inc. Files Patent Infringement Complaint in Federal Court Against Spectrum Brands ST. LOUIS, July 28 /PRNewswire-FirstCall/ -- Energizer Holdings, Inc., (NYSE: ENR), and the Eveready Battery Company, Inc. have filed a Complaint with the United States District Court Western District of Wisconsin. The Complaint is against Spectrum Brands and alleges patent infringement of patents owned by Energizer. Energizer believes that Spectrum Brands infringe Energizer's US Patents 5,290,414 and 6,849,360 by importing and selling primary lithium batteries in the United States. The alleged infringing products are manufactured and imported from China and bear the Rayovac Lithium brand. They have recently been made available for sale by Spectrum Brands at a major US retailer.

Alnylam Loses Challenge In Europe On Key Patent Covering Gene-Silencing Technology

July 14, 2008 (FinancialWire) Shares of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell after the company said that it lost a challenge in Europe on a key patent which covered certain areas of its gene-silencing technology. Alnylam said claims on the "Glover" patent were overturned by the Opposition Division of the European Patent Office. The patent is licensed from Cancer Research Technology Ltd. and Alnylam said it plans to appeal the decision. Alnylam said that the decision does not alter the position of the company's intellectual property for developing and commercializing RNAi therapeutics, nor does it impact any ongoing business development discussions. The patent is one of 11 held by Alnylam. The goal of gene-silencing, or RNA-based, treatments is to turn off, or silence- the gene at the root of a medical condition, treating the a

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

CORONA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings.

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

CORONA, Calif., August 13, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings.

Court: 'Violating Copyleft Is Copyright Infringement'

IconA federal appeals court has overruled a lower court ruling that, if sustained, would have severely hampered the enforceability of free software licenses. The lower court had found that redistributing software in violation of the terms of a free software license could constitute a breach of contract, but was not copyright infringement. The difference matters because copyright law affords much stronger remedies against infringement than does contract law. If allowed to stand, the decision could have neutered popular copyleft licenses such as the GPL and Creative Commons licenses. The district court decision was overturned on Wednesday by the United States Court of Appeals for the Federal Circuit.

Search took 0.69 seconds.